Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BME vs BTO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BME Captures Overall Composite Edge (40.9 SELL vs 43.7 HOLD), While BTO Leads 1–0 on Growth & Valuation Pillars

BME Overall Winner 6-Pillar Tally: BME 0 – 1 BTO (5 Tie) Matrix Metrics: BME 1 – 3 BTO

As of Nov 16, 2026, Blackrock Health Sciences Trust (BME) captures the overall head-to-head institutional edge over John Hancock Financial Opportunities Fund (BTO) on higher Unified Composite conviction (40.9/100 SELL vs. 43.7/100 HOLD) after splitting the core matrix 1–3 (led by composite factor balance), while BTO wins 1–0 across the 6-pillar growth and valuation breakdown. BME trades at $47.08 (N/M Forward P/E, N/A operating margin) versus BTO at $37.34 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While BTO currently prints a higher short-term Unified Composite Score (43.7/100 HOLD vs. BME 40.9/100 SELL), BME captures the overall institutional head-to-head verdict (1–3 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: BME trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.7); meanwhile BTO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BME vs BTO
BME NYSE Head-to-Head Winner
Blackrock Health Sciences Trust
Institutional Equity
$47.08
-1.07% 1D
Market Cap $487.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.42β · 19% Vol
Unified Composite Score
40.9 / 100 SELL
Tech 27.0 Fund 37.0 Flow 50.0 Mom 31.6
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.1% over 20 days), RSI 60
RSI-14: 59.7 · SMA20: $46.65 · SMA50: $45.16
BTO NYSE
John Hancock Financial Opportunities Fund
Institutional Equity
$37.34
-0.59% 1D
Market Cap $704.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.51β · 18% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 48.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.8%) with fading momentum, RSI 49
RSI-14: 49.3 · SMA20: $37.49 · SMA50: $37.16

6-Pillar Scorecard Institutional Category Breakdown (BME 0 – 1 BTO)

Columns: Metric · BME · BTO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BTO
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap $487.9M $704.9M
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BME (1) vs BTO (3)
Institutional Metric BME BTO Criterion Row Edge
Market Capitalization
Scale
$487.9M $704.9M Larger Scale BTO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
89% ($38–$48) 53% ($32–$42) Stronger Trend BME
Beta / 30D Volatility
Risk Regime
0.42β · 19% Vol 0.51β · 18% Vol Lower Realized Risk BTO
Unified Institutional Score
Composite Signal
40.9 / 100 (SELL) 43.7 / 100 (HOLD) Higher Composite BTO
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BME +3.0 pp
BME: +6.98% · BTO: +3.98%
3M Horizon BME +13.9 pp
BME: +4.95% · BTO: -8.95%
6M Horizon BME +18.26 pp
BME: +21.87% · BTO: +3.61%
1Y Horizon BME +4.0 pp
BME: +16.71% · BTO: +12.71%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BME vs BTO. Trailing 12-month operating profitability (BME N/A vs BTO N/A) and valuation multiples (BME N/M vs BTO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BME ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BTO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BME UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BTO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BTO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BME Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $487.9M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BTO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $704.9M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BME vs BTO Key Questions & Quantitative Answers

As of Nov 16, 2026, Blackrock Health Sciences Trust (BME) captures the overall head-to-head institutional edge over John Hancock Financial Opportunities Fund (BTO) on higher Unified Composite conviction (40.9/100 SELL vs. 43.7/100 HOLD) after splitting the core matrix 1–3 (led by composite factor balance), while BTO wins 1–0 across the 6-pillar growth and valuation breakdown. BME trades at $47.08 (N/M Forward P/E, N/A operating margin) versus BTO at $37.34 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While BTO currently prints a higher short-term Unified Composite Score (43.7/100 HOLD vs. BME 40.9/100 SELL), BME captures the overall institutional head-to-head verdict (1–3 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: BME trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.7); meanwhile BTO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BTO leads the Growth & Scale pillar: BME posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BTO at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BME generates N/A in USD-normalized revenue versus N/A for BTO. In operating R&D and SG&A reinvestment, BME deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BTO.

BME and BTO trade at balanced relative valuation multiples. BME trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BTO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BME (N/A ROE) versus BTO (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, BME carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.42β · 19% Vol realized risk). By comparison, BTO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.51β · 18% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.